ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
126.134,94
-0,61%
S&P 500
6.040,53
-0,50%
US Dollar vs BRL
5,842
0,00%
Bitcoin
102.524,43
0,11%
Brent Oil
76,385
0,00%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Anavex Life Sciences Corporation (AVXL)

  7. Anavex Life Sciences Corporation (AVXL) Notícias

AVXL

Anavex Life Sciences (AVXL)

Anavex Life Sciences Corporation
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AVXL
DataHoraFonteTítuloCódigoCompanhia
27/01/202509:30GlobeNewswire Inc.Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property PortfolioNASDAQ:AVXLAnavex Life Sciences Corporation
17/01/202523:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVXLAnavex Life Sciences Corporation
15/01/202509:30GlobeNewswire Inc.Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s DiseaseNASDAQ:AVXLAnavex Life Sciences Corporation
13/01/202509:30GlobeNewswire Inc.New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease PatientsNASDAQ:AVXLAnavex Life Sciences Corporation
06/01/202509:30GlobeNewswire Inc.Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AVXLAnavex Life Sciences Corporation
23/12/202418:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AVXLAnavex Life Sciences Corporation
23/12/202409:30GlobeNewswire Inc.Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business UpdateNASDAQ:AVXLAnavex Life Sciences Corporation
23/12/202409:00GlobeNewswire Inc.Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s DiseaseNASDAQ:AVXLAnavex Life Sciences Corporation
16/12/202409:30GlobeNewswire Inc.Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024NASDAQ:AVXLAnavex Life Sciences Corporation
09/12/202409:30GlobeNewswire Inc.Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare ConferenceNASDAQ:AVXLAnavex Life Sciences Corporation
02/12/202409:30GlobeNewswire Inc.Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024NASDAQ:AVXLAnavex Life Sciences Corporation
26/11/202409:30GlobeNewswire Inc.Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMANASDAQ:AVXLAnavex Life Sciences Corporation
25/11/202409:30GlobeNewswire Inc.Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease JournalNASDAQ:AVXLAnavex Life Sciences Corporation
31/10/202405:00GlobeNewswire Inc.Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024NASDAQ:AVXLAnavex Life Sciences Corporation
23/10/202409:03InvestorsHub NewsWireZenaTech, Inc. (NASDAQ: ZENA) Software Company AcquisitionNASDAQ:AVXLAnavex Life Sciences Corporation
17/10/202408:30GlobeNewswire Inc.Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of SchizophreniaNASDAQ:AVXLAnavex Life Sciences Corporation
15/10/202409:21InvestorsHub NewsWireZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory ManagementNASDAQ:AVXLAnavex Life Sciences Corporation
01/10/202408:00InvestorsHub NewsWireZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading TodayNASDAQ:AVXLAnavex Life Sciences Corporation
03/09/202408:30GlobeNewswire Inc.Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024NASDAQ:AVXLAnavex Life Sciences Corporation
06/08/202418:21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVXLAnavex Life Sciences Corporation
06/08/202408:30GlobeNewswire Inc.Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business UpdateNASDAQ:AVXLAnavex Life Sciences Corporation
01/08/202408:30GlobeNewswire Inc.Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024NASDAQ:AVXLAnavex Life Sciences Corporation
30/07/202418:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVXLAnavex Life Sciences Corporation
30/07/202408:30GlobeNewswire Inc.Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X ConferenceNASDAQ:AVXLAnavex Life Sciences Corporation
29/07/202418:21Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:AVXLAnavex Life Sciences Corporation
28/07/202418:00GlobeNewswire Inc.Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association ConferenceNASDAQ:AVXLAnavex Life Sciences Corporation
20/06/202408:30GlobeNewswire Inc.Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceNASDAQ:AVXLAnavex Life Sciences Corporation
22/05/202408:30GlobeNewswire Inc.Anavex Life Sciences Announces Expansion of Leadership TeamNASDAQ:AVXLAnavex Life Sciences Corporation
14/05/202408:30GlobeNewswire Inc.Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQNASDAQ:AVXLAnavex Life Sciences Corporation
10/05/202406:45PR Newswire (US)Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreNASDAQ:AVXLAnavex Life Sciences Corporation
 Apresentando as notícias mais relevantes sobre:NASDAQ:AVXL

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios